Media & Events
Shardul Amarchand Mangaldas represents Apollo Hospitals Enterprise Limited, Apollo Healthco Limited and Keimed Private Limited before the Competition Commission of India in Advent International L.P.’s investment in Apollo Healthco, Apollo Healthco’s investment in Keimed and the merger of Keimed into Apollo Healthco
September 2, 2024
Shardul Amarchand Mangaldas & Co. successfully represented Apollo Hospitals Enterprise Limited (AHEL), Apollo Healthco Limited (AHL) and Keimed Private Limited (Keimed) before the Competition Commission of India (CCI) in Advent International L.P.’s investment (through Rasmeli Limited (Rasmeli)) in AHL, AHL’s investment in Keimed and Keimed’s merger into AHL.
The transaction will result in the creation of a combined entity with an efficient and diversified supply chain, which will provide customers across India access to medicines, and involves the following steps:
- Primary investment by Advent of INR 2,475 crore (approx. US$ 300 million);
- Primary and secondary investment in Keimed of INR 725 crore (approx. US$ 8.6 million); and
- Amalgamation of Keimed in AHL at the (current) combined enterprise valuation of INR 22,481 crore (approx. US$ 2.7 billion).
The combination received unconditional Phase I approval from the CCI on 20 August 2024.
The Shardul Amarchand Mangaldas & Co. competition team was led by Partners Harman Singh Sandhu and Rohan Arora; Principal Associate Sonali Charak; Senior Associate Apurv Jain; and Associates Arjav Kulshreshtha and Aryika Dadhwal.
